Research Shows Long-Term Benefit for Adjuvant Targeted Therapies in High-Risk Melanoma

Source: Cancer Therapy Advisor, October 2020

When oncologists discuss melanoma patients’ options with them following treatment, it’s often not clear whether adjuvant therapy is the best choice.

Patients must consider whether it’s worth enduring side effects or relying on close monitoring in the event of recurrence.

“The big question is always whether there’s an advantage to trying it in the adjuvant setting,” said Paul B. Chapman, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center in New York who specializes in treating melanoma.

READ THE ORIGINAL FULL ARTICLE